ADXN
Addex Therapeutics LtdNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.81
P/S
46.57
EV/EBITDA
-0.70
DCF Value
$3.98
FCF Yield
-24.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
-14.1%
Operating Margin
-1789.2%
Net Margin
-4397.0%
ROE
-78.3%
ROA
-83.2%
ROIC
-40.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $29.7K | $-1.6M | $-1.67 |
| Q2 2025 | $36.4K | $-1.8M | $-2.40 |
| Q1 2025 | $0.00 | $-1.5M | $-1.80 |
| Q4 2024 | $1.5K | $-1.2M | $-1.48 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
CH
Exchange
NASDAQ
Beta
1.86
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.